Eli Lilly and Company (NYSE:LLY) CAO Donald Zakrowski Sells 2,000 Shares

Eli Lilly and Company (NYSE:LLY) CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,212.96 on Wednesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The firm’s 50-day simple moving average is $1,165.35 and its 200-day simple moving average is $1,049.90. Eli Lilly and Company has a twelve month low of $629.40 and a twelve month high of $1,249.45. The firm has a market cap of $1.14 trillion, a P/E ratio of 40.70, a price-to-earnings-growth ratio of 1.45 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts expect that Eli Lilly and Company will post 36.33 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 23.22%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently bought and sold shares of the business. Norges Bank acquired a new position in Eli Lilly and Company during the 4th quarter worth about $12,976,634,000. J. Stern & Co. LLP increased its position in Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after acquiring an additional 4,038,502 shares in the last quarter. Cardano Risk Management B.V. increased its position in Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after acquiring an additional 2,131,734 shares in the last quarter. Fifth Third Bancorp raised its stake in shares of Eli Lilly and Company by 321.3% in the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after acquiring an additional 1,497,423 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Eli Lilly and Company by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after acquiring an additional 1,432,069 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on LLY. Rothschild & Co Redburn boosted their price target on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research note on Friday. Sanford C. Bernstein lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a report on Tuesday, July 14th. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, July 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,292.18.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. approved Lilly’s oral GLP-1 drug Foundayo for weight loss and weight maintenance in eligible adults. This is the pill’s first approval outside the United States and opens a large international market, although initial access will be primarily through private prescriptions while NHS coverage undergoes a cost-effectiveness review. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: Investors continue to cite Lilly’s strong second-quarter results as a foundation for further upside. Revenue increased 47.7% year over year to $22.97 billion, while earnings per share of $8.38 exceeded the $6.40 consensus estimate. Fiscal 2026 EPS guidance stands at $35.50–$36.50, supported by demand for Mounjaro, Zepbound and the broader obesity-drug portfolio. Eli Lilly Beat Big and Raised Guidance
• Positive Sentiment: Lilly participated in a $100 million financing for Absci, including a $40 million strategic investment. The partnership could provide exposure to Absci’s drug-discovery platform, though it is not expected to materially affect Lilly’s near-term financial results. Absci Reports Business Updates
• Neutral Sentiment: Analyst views remain broadly favorable, with recent price-target increases and a consensus “Moderate Buy” rating. However, the stock’s elevated valuation means additional gains may depend on continued earnings beats and successful international commercialization of Foundayo. Eli Lilly Fair Value Bump
• Negative Sentiment: Erste Group Bank lowered its 2026 EPS estimate to $34.93 from $35.34, below the company’s guidance range and the broader consensus estimate of $36.77. The reduction introduces a modest cautionary note after Lilly’s recent rally. Eli Lilly analyst estimates
• Negative Sentiment: Two executives reported stock sales totaling approximately $8.32 million. Both transactions were executed under pre-arranged Rule 10b5-1 plans, which limits their value as evidence of weakening confidence, but the sales may still weigh marginally on sentiment. SEC Form 4 Filing

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.